drugset / Trial / NCT03456908

F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies

NCT03456908 ↗

Phase 1 Completed 2 enrolled Mayo Clinic
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues. .

Timeline

Start
2018-03-16
Primary completion
2019-12-31
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject F-18 tetrafluoroborate Diagnostic / imaging agent — Other